s
s
s
Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug canakinumab (Ilaris) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Canakinumab
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Canakinumab Inhibitory Type 1 |
HCA417 |
AbD54331ia |
hIgG1 |
1.5 |
ADA assay |
|
HCA418 |
AbD54111ia |
hIgG1 |
7.7 |
ADA assay |
||
HCA419 |
AbD54116ia |
hIgG1 |
9.6 |
ADA assay |
||
TZA063 |
AbD54116ad |
Fab-F-Spy2-H1 |
9.6 |
PK bridging ELISA (capture) |
||
TZA064 |
AbD54331ad |
Fab-F-Spy2-H1 |
1.5 |
PK bridging ELISA (detection) |
||
TZA064P |
AbD54331pap |
Fab2-FH-X22-HRP2 |
1.5 |
PK bridging ELISA (detection) |
Order TZA064P |
* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP conjugated BiCatcher.
Type 1 anti-canakinumab antibodies inhibit the binding of the drug canakinumab to its target, the human interleukin-1β (IL-1β). They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibodies in fully human IgG1 format are suitable as surrogate positive controls or calibrators for an anti-drug antibody (ADA) assay.
Fig. 1. Canakinumab PK bridging ELISA using antibodies TZA063 and TZA064P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.
Fig. 2. Canakinumab ADA bridging ELISA using antibodies HCA417, HCA418, and HCA419.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.